Literature DB >> 16034890

Continuous infusion versus bolus injection of loop diuretics in congestive heart failure.

D R K Salvador1, N R Rey, G C Ramos, F E R Punzalan.   

Abstract

BACKGROUND: Loop diuretics, when given as intermittent bolus injections in acutely decompensated heart failure, may cause fluctuations in intravascular volume, increased toxicity and development of tolerance. Continuous infusion has been proposed to avoid these complications and result in greater diuresis, hopefully leading to faster symptom resolution, decrease in morbidity and possibly, mortality.
OBJECTIVES: To compare the effects and adverse effects of continuous intravenous infusion of loop diuretics with those of bolus intravenous administration among patients with congestive heart failure Class III-IV. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2003), MEDLINE (1966 to 2003), EMBASE (1980 to 2003) and the HERDIN database. We also contacted pharmaceutical companies . SELECTION CRITERIA: Randomized controlled trials comparing the efficacy of continuous intravenous infusion versus bolus intravenous administration of loop diuretics in congestive heart failure were included DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed study eligibility, methodological quality and did data extraction. Included studies were assessed for validity. Authors were contacted when feasible. Adverse effects information was collected from the trials. MAIN
RESULTS: Eight trials involving 254 patients were included. In seven studies which reported on urine output, the output (as measured in cc/24 hours) was noted to be greater in patients given continuous infusion with a weighted mean difference (WMD) of 271 cc/24 hour (95%CI 93.1 to 449; p<0.01). Electrolyte disturbances (hypokalemia, hypomagnesemia) were not significantly different in the two treatment groups with a relative risk (RR) of 1.47 (95%CI 0.52 to 4.15; p=0.5). Less adverse effects (tinnitus and hearing loss) were noted when continuous infusion was given, RR 0.06 (95%CI 0.01 to 0.44; p=0.005). Based on a single study, the duration of hospital stay was significantly shortened by 3.1days with continuous infusion WMD -3.1 (95%CI -4.06 to -2.20; p<0.0001) while cardiac mortality was significantly different in the two treatment groups, RR 0.47 (95% CI 0.33 to 0.69; p<0.0001). Based on two studies, all cause mortality was significantly different in the two treatment groups, RR 0.52 (95%CI 0.38 to 0.71; p<0.0001). AUTHORS'
CONCLUSIONS: Currently available data are insufficient to confidently assess the merits of the two methods of giving intravenous diuretics. Based on small and relatively heterogenous studies, this review showed greater diuresis and a better safety profile when loop diuretics were given as continuous infusion. The existing data still does not allow definitive recommendations for clinical practice and larger studies should be done to more adequately settle this issue.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034890      PMCID: PMC8094162          DOI: 10.1002/14651858.CD003178.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  26 in total

1.  Severe musculoskeletal symptoms during continuous infusion of bumetanide.

Authors:  P A Howard; M I Dunn
Journal:  Chest       Date:  1997-02       Impact factor: 9.410

2.  Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion.

Authors:  T P Dormans; J J van Meyel; P G Gerlag; Y Tan; F G Russel; P Smits
Journal:  J Am Coll Cardiol       Date:  1996-08       Impact factor: 24.094

3.  Diuresis with continuous infusion of furosemide after cardiac surgery.

Authors:  J G Copeland; D W Campbell; J R Plachetka; N W Salomon; D F Larson
Journal:  Am J Surg       Date:  1983-12       Impact factor: 2.565

4.  Protocol-guided diuretic management: comparison of furosemide by continuous infusion and intermittent bolus.

Authors:  D Schuller; J P Lynch; D Fine
Journal:  Crit Care Med       Date:  1997-12       Impact factor: 7.598

5.  Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.

Authors:  Giuseppe Licata; Pietro Di Pasquale; Gaspare Parrinello; Antonietta Cardinale; Angela Scandurra; Giuseppe Follone; Christiano Argano; Antonino Tuttolomondo; Salvatore Paterna
Journal:  Am Heart J       Date:  2003-03       Impact factor: 4.749

6.  Role of duration of diuretic effect in preventing sodium retention.

Authors:  J A Ferguson; K J Sundblad; P K Becker; J C Gorski; D W Rudy; D C Brater
Journal:  Clin Pharmacol Ther       Date:  1997-08       Impact factor: 6.875

7.  Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure.

Authors:  E Aaser; L Gullestad; S Tølløfsrud; J Lundberg; C Hall; O Djøseland; J Kjekshus; K Forfang
Journal:  Scand J Clin Lab Invest       Date:  1997-07       Impact factor: 1.713

8.  Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure.

Authors:  N Pivac; Z Rumboldt; S Sardelić; J Bagatin; S Polić; D Ljutić; M Naranca; V Capkun
Journal:  Int J Clin Pharmacol Res       Date:  1998

9.  Development of acute tolerance to bumetanide: constant-rate infusion studies.

Authors:  J A Cook; D E Smith
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

Review 10.  The role of continuous infusion loop diuretics.

Authors:  S L Yelton; M A Gaylor; K M Murray
Journal:  Ann Pharmacother       Date:  1995-10       Impact factor: 3.154

View more
  39 in total

1.  Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure.

Authors:  Larry A Allen; Aslan T Turer; Tracy Dewald; Wendy Gattis Stough; Gadi Cotter; Christopher M O'Connor
Journal:  Am J Cardiol       Date:  2010-04-27       Impact factor: 2.778

2.  What have we learned about loop diuretics in acute decompensated heart failure? The DOSE trial.

Authors:  Dmitry Shchekochikhin; JoAnn Lindenfeld
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

3.  Evolving treatment strategies for management of cardiorenal syndrome.

Authors:  Sanjay Dandamudi; Horng H Chen
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-12

4.  Management of the cardiorenal syndrome in acute heart failure.

Authors:  Valentina Lazzarini; G Michael Felker
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

Review 5.  Contemporary strategies in the diagnosis and management of heart failure.

Authors:  Shannon M Dunlay; Naveen L Pereira; Sudhir S Kushwaha
Journal:  Mayo Clin Proc       Date:  2014-03-29       Impact factor: 7.616

Review 6.  Management of acute decompensated heart failure.

Authors:  Larry A Allen; Christopher M O'Connor
Journal:  CMAJ       Date:  2007-03-13       Impact factor: 8.262

7.  Optimal use of diuretics in patients with heart failure.

Authors:  Jigar Patel; Michael Smith; J Thomas Heywood
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

Review 8.  Managing acute renal failure in patients with acute decompensated heart failure: the cardiorenal syndrome.

Authors:  Ravi V Shah; Michael M Givertz
Journal:  Curr Heart Fail Rep       Date:  2009-09

9.  A patient with heart failure and worsening kidney function.

Authors:  Mark J Sarnak
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-24       Impact factor: 8.237

Review 10.  Loop diuretics in heart failure.

Authors:  G Michael Felker
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.